ANI Pharmaceuticals Analyst Ratings
ANI Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/19/2023 | 25.15% | Guggenheim | → $72 | Reiterates | Buy → Buy |
| 09/13/2023 | 25.15% | Guggenheim | → $72 | Reiterates | Buy → Buy |
| 08/22/2023 | 26.89% | HC Wainwright & Co. | $60 → $73 | Maintains | Buy |
| 08/21/2023 | 21.68% | Truist Securities | → $70 | Reiterates | Buy → Buy |
| 08/10/2023 | 25.15% | Guggenheim | $62 → $72 | Maintains | Buy |
| 07/27/2023 | 7.77% | Guggenheim | $59 → $62 | Maintains | Buy |
| 07/21/2023 | 4.29% | Truist Securities | $52 → $60 | Maintains | Buy |
| 05/09/2023 | 2.56% | Guggenheim | $55 → $59 | Maintains | Buy |
| 05/09/2023 | -9.61% | Truist Securities | $50 → $52 | Maintains | Buy |
| 05/09/2023 | -14.83% | Raymond James | $48 → $49 | Maintains | Outperform |
| 05/09/2023 | 4.29% | HC Wainwright & Co. | $53 → $60 | Maintains | Buy |
| 03/13/2023 | -7.87% | HC Wainwright & Co. | $50 → $53 | Maintains | Buy |
| 03/01/2023 | -4.4% | Guggenheim | → $55 | Initiates Coverage On | → Buy |
| 02/21/2023 | -13.09% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 09/07/2022 | -13.09% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 08/09/2022 | -16.57% | Raymond James | $47 → $48 | Maintains | Outperform |
| 03/16/2022 | -18.3% | Raymond James | $65 → $47 | Maintains | Outperform |
| 11/02/2021 | 12.98% | Raymond James | $60 → $65 | Maintains | Outperform |
| 11/02/2021 | 21.68% | Truist Securities | → $70 | Initiates Coverage On | → Buy |
| 05/10/2021 | 4.29% | Raymond James | $40 → $60 | Maintains | Outperform |
| 08/03/2020 | -30.47% | Raymond James | $49 → $40 | Maintains | Outperform |
| 05/08/2020 | -14.83% | Raymond James | $65 → $49 | Maintains | Outperform |
| 05/07/2020 | -30.47% | Cantor Fitzgerald | $78 → $40 | Downgrades | Overweight → Neutral |
| 04/30/2020 | 0.82% | Guggenheim | $62 → $58 | Maintains | Buy |
| 02/28/2020 | 12.98% | Raymond James | $75 → $65 | Maintains | Outperform |
| 11/07/2019 | 30.37% | Raymond James | $82 → $75 | Maintains | Outperform |
| 09/12/2019 | 32.1% | Guggenheim | → $76 | Initiates Coverage On | → Buy |
| 05/10/2019 | 42.53% | Raymond James | $73 → $82 | Downgrades | Strong Buy → Outperform |
| 11/12/2018 | 21.68% | Canaccord Genuity | $75 → $70 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月19日 | 25.15% | 古根海姆 | →$72 | 重申 | 购买→购买 |
| 09/13/2023 | 25.15% | 古根海姆 | →$72 | 重申 | 购买→购买 |
| 2023年08月22日 | 26.89% | HC Wainwright公司 | $60→$73 | 维护 | 买 |
| 2023年08月21日 | 21.68% | Truist证券 | →$70 | 重申 | 购买→购买 |
| 2023年08月10日 | 25.15% | 古根海姆 | $62→$72 | 维护 | 买 |
| 07/27/2023 | 7.77% | 古根海姆 | $59→$62 | 维护 | 买 |
| 07/21/2023 | 4.29% | Truist证券 | $52→$60 | 维护 | 买 |
| 05/09/2023 | 2.56% | 古根海姆 | $55→$59 | 维护 | 买 |
| 05/09/2023 | -9.61% | Truist证券 | $50→$52 | 维护 | 买 |
| 05/09/2023 | -14.83% | 雷蒙德·詹姆斯 | $48→$49 | 维护 | 跑赢大盘 |
| 05/09/2023 | 4.29% | HC Wainwright公司 | $53→$60 | 维护 | 买 |
| 03/13/2023 | -7.87% | HC Wainwright公司 | $50→$53 | 维护 | 买 |
| 03/01/2023 | -4.4% | 古根海姆 | →$55 | 开始承保 | →购买 |
| 02/21/2023 | -13.09% | HC Wainwright公司 | →$50 | 重申 | →购买 |
| 09/07/2022 | -13.09% | HC Wainwright公司 | →$50 | 开始承保 | →购买 |
| 08/09/2022 | -16.57% | 雷蒙德·詹姆斯 | $47→$48 | 维护 | 跑赢大盘 |
| 03/16/2022 | -18.3% | 雷蒙德·詹姆斯 | $65→$47 | 维护 | 跑赢大盘 |
| 11/02/2021 | 12.98% | 雷蒙德·詹姆斯 | $60→$65 | 维护 | 跑赢大盘 |
| 11/02/2021 | 21.68% | Truist证券 | →$70 | 开始承保 | →购买 |
| 2021/05/10 | 4.29% | 雷蒙德·詹姆斯 | $40→$60 | 维护 | 跑赢大盘 |
| 08/03/2020 | -30.47% | 雷蒙德·詹姆斯 | $49→$40 | 维护 | 跑赢大盘 |
| 05/08/2020 | -14.83% | 雷蒙德·詹姆斯 | $65→$49 | 维护 | 跑赢大盘 |
| 05/07/2020 | -30.47% | 康托·菲茨杰拉德 | $78→$40 | 评级下调 | 超重→中性 |
| 04/30/2020 | 0.82% | 古根海姆 | $62→$58 | 维护 | 买 |
| 02/28/2020 | 12.98% | 雷蒙德·詹姆斯 | $75→$65 | 维护 | 跑赢大盘 |
| 2019/07/11 | 30.37% | 雷蒙德·詹姆斯 | $82→$75 | 维护 | 跑赢大盘 |
| 2019/12/09 | 32.1% | 古根海姆 | →$76 | 开始承保 | →购买 |
| 2019年5月10日 | 42.53% | 雷蒙德·詹姆斯 | $73→$82 | 评级下调 | 强势买入→跑赢大盘 |
| 2018年11月12日 | 21.68% | 卡纳科特·格纳奇 | $75→$70 | 维护 | 买 |
What is the target price for ANI Pharmaceuticals (ANIP)?
ANI制药(ANIP)的目标价是多少？
The latest price target for ANI Pharmaceuticals (NASDAQ: ANIP) was reported by Guggenheim on October 19, 2023. The analyst firm set a price target for $72.00 expecting ANIP to rise to within 12 months (a possible 25.15% upside). 14 analyst firms have reported ratings in the last year.
古根海姆于2023年10月19日报道了ANI制药(纳斯达克：ANIP)的最新目标价。这家分析公司将目标价定为72.00美元，预计Anip将在12个月内上涨(可能上涨25.15%)。过去一年，有14家分析公司公布了评级。
What is the most recent analyst rating for ANI Pharmaceuticals (ANIP)?
ANI制药(ANIP)的最新分析师评级是多少？
The latest analyst rating for ANI Pharmaceuticals (NASDAQ: ANIP) was provided by Guggenheim, and ANI Pharmaceuticals reiterated their buy rating.
古根海姆提供了对ANI制药(纳斯达克代码：ANIP)的最新分析师评级，ANI制药重申了其买入评级。
When is the next analyst rating going to be posted or updated for ANI Pharmaceuticals (ANIP)?
ANI制药(ANIP)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ANI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ANI Pharmaceuticals was filed on October 19, 2023 so you should expect the next rating to be made available sometime around October 19, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与ANI制药的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。ANI制药的上一次评级是在2023年10月19日提交的，所以你应该预计下一次评级将在2024年10月19日左右的某个时候公布。
Is the Analyst Rating ANI Pharmaceuticals (ANIP) correct?
分析师对ANI制药(ANIP)的评级正确吗？
While ratings are subjective and will change, the latest ANI Pharmaceuticals (ANIP) rating was a reiterated with a price target of $0.00 to $72.00. The current price ANI Pharmaceuticals (ANIP) is trading at is $57.53, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的ANI制药(ANIP)评级被重申，目标价在0.00美元至72.00美元之间。ANI制药(ANIP)目前的交易价格为57.53美元，在分析师的预测区间内。